Progress on haptoglobin and metabolic diseases

被引:26
|
作者
Wan, Bao-Nian [1 ]
Zhou, Shi-Gao [1 ]
Wang, Miao [1 ]
Zhang, Xiao [1 ]
Ji, Guang [2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept TCM Demonstrat, Shanghai 200032, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Inst Digest Dis, Longhua Hosp, 725 Wanping South Rd, Shanghai 200032, Peoples R China
关键词
Haptoglobin; Polymorphism; Metabolic diseases; Simple obesity; Inflammation; CD163; ADIPOSE-TISSUE; OBESITY; ASSOCIATION; PLASMA;
D O I
10.4239/wjd.v12.i3.206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haptoglobin (Hp) is an acidic glycoprotein, existing in the serum and other body fluids of human beings and a variety of mammals. Hp is produced in the liver, white adipose tissue, and the kidney. The genetic polymorphisms and different phenotypes of Hp have different biological functions. Hp has antibacterial, antioxidant, and angiogenic effects and is associated with multiple diseases including simple obesity, vascular complications of diabetes mellitus, nonalcoholic fatty liver disease, hypertension, blood diseases, autoimmune diseases, and malignant tumors. Hp also participates in many life activities, indicating the importance of Hp in further studies. Previously, we found that the expression of serum Hp changed after treatment of simple obesity patients in clinical trials. However, the specific mechanism of Hp in patients with simple obesity is still unclear. The purpose of this article is to introduce recent research progress on Hp, emphasizing the relationship between Hp and the development of metabolic disease, which will improve the understanding of the functions of Hp underlying metabolic diseases and discuss future research directions.
引用
收藏
页码:206 / 214
页数:9
相关论文
共 50 条
  • [1] Celastrol in metabolic diseases: Progress and application prospects
    Xu, Shaohua
    Feng, Yaqian
    He, Weishen
    Xu, Wen
    Xu, Wei
    Yang, Hongjun
    Li, Xianyu
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [2] Oral microbiota-induced periodontitis: a new risk factor of metabolic diseases
    Minty, Matthieu
    Canceil, Thibault
    Serino, Matteo
    Burcelin, Remy
    Terce, Francois
    Blasco-Baque, Vincent
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2019, 20 (04) : 449 - 459
  • [3] Evaluation of serum haptoglobin levels and Hp1-Hp2 polymorphism in the haptoglobin gene in patients with atrial fibrillation
    Xavier Costa, Luana Bernardes
    Martins, Gabriela Lopes
    Figueiredo Duarte, Rita Carolina
    Rocha, Pamella Lemos
    Figueiredo, Estevao Lanna
    Silveira, Francisco Rezende
    Carvalho, Maria das Gracas
    Reis, Helton Jose
    Gomes, Karina Braga
    Ferreira, Claudia Natalia
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (08) : 7359 - 7365
  • [4] Current Progress of Lipid Analysis in Metabolic Diseases by Mass Spectrometry Methods
    Mika, Adriana
    Sledzinski, Tomasz
    Stepnowski, Piotr
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (01) : 60 - 103
  • [5] Haptoglobin polymorphism in Korean patients with cardiovascular diseases
    Hong, SH
    Kang, BY
    Lim, JH
    Namkoong, Y
    Oh, MY
    Kim, JQ
    Lee, CC
    HUMAN HEREDITY, 1997, 47 (05) : 283 - 287
  • [6] Haptoglobin levels are influenced by Hp1-Hp2 polymorphism, obesity, inflammation, and hypertension in type 2 diabetes mellitus
    Rodrigues, Kathryna Fontana
    Pietrani, Nathalia Teixeira
    Carvalho, Laura Machado Lara
    Bosco, Adriana Aparecida
    Sandrim, Valeria Cristina
    Ferreira, Claudia Natalia
    Gomes, Karina Braga
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2019, 66 (02): : 99 - 107
  • [7] Atf3 induction is a therapeutic target for obesity and metabolic diseases
    Kim, Suji
    Song, No-Joon
    Bahn, Gahee
    Chang, Seo-Hyuk
    Yun, Ui Jeong
    Ku, Jin-Mo
    Jo, Dong-Gyu
    Park, Kye Won
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 504 (04) : 903 - 908
  • [8] Contribution of Macrophage Polarization to Metabolic Diseases
    Komohara, Yoshihiro
    Fujiwara, Yukio
    Ohnishi, Koji
    Shiraishi, Daisuke
    Takeya, Motohiro
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2016, 23 (01) : 10 - 17
  • [9] Aquaglyceroporins: Drug Targets for Metabolic Diseases?
    Calamita, Giuseppe
    Perret, Jason
    Delporte, Christine
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [10] Progress in the Application and Scheme of the Ketogenic Diet in the Treatment of Metabolic Diseases
    Li Y.
    Zhou Y.
    Shan Y.
    Huang S.
    Zhou L.
    Li J.
    Science and Technology of Food Industry, 2023, 44 : 352 - 359